nodes	percent_of_prediction	percent_of_DWPC	metapath
Zalcitabine—Bell's palsy—Octreotide—thymus cancer	0.134	0.143	CcSEcCtD
Zalcitabine—Vaginal itching—Octreotide—thymus cancer	0.0598	0.0634	CcSEcCtD
Zalcitabine—Vulvovaginal pruritus—Octreotide—thymus cancer	0.0371	0.0393	CcSEcCtD
Zalcitabine—VIIth nerve paralysis—Octreotide—thymus cancer	0.0197	0.0209	CcSEcCtD
Zalcitabine—Pancreatitis acute—Octreotide—thymus cancer	0.0175	0.0186	CcSEcCtD
Zalcitabine—Proctalgia—Octreotide—thymus cancer	0.0173	0.0183	CcSEcCtD
Zalcitabine—Abdominal bloating—Octreotide—thymus cancer	0.017	0.018	CcSEcCtD
Zalcitabine—Epigastric pain—Octreotide—thymus cancer	0.0167	0.0178	CcSEcCtD
Zalcitabine—Loose stools—Octreotide—thymus cancer	0.0146	0.0155	CcSEcCtD
Zalcitabine—Cholecystitis—Octreotide—thymus cancer	0.0141	0.015	CcSEcCtD
Zalcitabine—Haemorrhoids—Octreotide—thymus cancer	0.0138	0.0146	CcSEcCtD
Zalcitabine—Nail disorder—Octreotide—thymus cancer	0.0125	0.0132	CcSEcCtD
Zalcitabine—Paranoia—Octreotide—thymus cancer	0.0119	0.0126	CcSEcCtD
Zalcitabine—Neuralgia—Octreotide—thymus cancer	0.0116	0.0124	CcSEcCtD
Zalcitabine—Influenza-like symptoms—Octreotide—thymus cancer	0.0113	0.012	CcSEcCtD
Zalcitabine—Throat sore—Octreotide—thymus cancer	0.0112	0.0119	CcSEcCtD
Zalcitabine—Oropharyngeal discomfort—Octreotide—thymus cancer	0.0111	0.0118	CcSEcCtD
Zalcitabine—Neuritis—Octreotide—thymus cancer	0.0108	0.0115	CcSEcCtD
Zalcitabine—Nephrolithiasis—Octreotide—thymus cancer	0.0101	0.0107	CcSEcCtD
Zalcitabine—Rectal haemorrhage—Octreotide—thymus cancer	0.00896	0.00951	CcSEcCtD
Zalcitabine—Arthropathy—Octreotide—thymus cancer	0.0089	0.00944	CcSEcCtD
Zalcitabine—Cellulitis—Octreotide—thymus cancer	0.0089	0.00944	CcSEcCtD
Zalcitabine—Oropharyngeal pain—Octreotide—thymus cancer	0.0089	0.00944	CcSEcCtD
Zalcitabine—Hyperbilirubinaemia—Octreotide—thymus cancer	0.0089	0.00944	CcSEcCtD
Zalcitabine—Hearing impaired—Octreotide—thymus cancer	0.0085	0.00902	CcSEcCtD
Zalcitabine—Muscle twitching—Octreotide—thymus cancer	0.00824	0.00874	CcSEcCtD
Zalcitabine—Phosphatase alkaline increased—Octreotide—thymus cancer	0.00809	0.00859	CcSEcCtD
Zalcitabine—Hyperkalaemia—Octreotide—thymus cancer	0.00795	0.00844	CcSEcCtD
Zalcitabine—Eructation—Octreotide—thymus cancer	0.00795	0.00844	CcSEcCtD
Zalcitabine—Wheezing—Octreotide—thymus cancer	0.00786	0.00834	CcSEcCtD
Zalcitabine—Influenza like illness—Octreotide—thymus cancer	0.00786	0.00834	CcSEcCtD
Zalcitabine—Candida infection—Octreotide—thymus cancer	0.00773	0.0082	CcSEcCtD
Zalcitabine—Vaginal infection—Octreotide—thymus cancer	0.00764	0.00811	CcSEcCtD
Zalcitabine—Cramps of lower extremities—Octreotide—thymus cancer	0.00743	0.00789	CcSEcCtD
Zalcitabine—Bladder pain—Octreotide—thymus cancer	0.00732	0.00776	CcSEcCtD
Zalcitabine—Urine output increased—Octreotide—thymus cancer	0.00732	0.00776	CcSEcCtD
Zalcitabine—Hyperkinesia—Octreotide—thymus cancer	0.00706	0.00749	CcSEcCtD
Zalcitabine—Diabetes mellitus—Octreotide—thymus cancer	0.00675	0.00717	CcSEcCtD
Zalcitabine—Blood alkaline phosphatase increased—Octreotide—thymus cancer	0.00675	0.00717	CcSEcCtD
Zalcitabine—Polyuria—Octreotide—thymus cancer	0.00669	0.0071	CcSEcCtD
Zalcitabine—Deafness—Octreotide—thymus cancer	0.00657	0.00697	CcSEcCtD
Zalcitabine—Hot flush—Octreotide—thymus cancer	0.00628	0.00666	CcSEcCtD
Zalcitabine—Amnesia—Octreotide—thymus cancer	0.00625	0.00663	CcSEcCtD
Zalcitabine—Menopausal symptoms—Octreotide—thymus cancer	0.00623	0.00661	CcSEcCtD
Zalcitabine—Arthritis—Octreotide—thymus cancer	0.00604	0.00641	CcSEcCtD
Zalcitabine—Hypoglycaemia—Octreotide—thymus cancer	0.00602	0.00639	CcSEcCtD
Zalcitabine—Pain in extremity—Octreotide—thymus cancer	0.00587	0.00623	CcSEcCtD
Zalcitabine—Gastrointestinal haemorrhage—Octreotide—thymus cancer	0.00587	0.00623	CcSEcCtD
Zalcitabine—Osteoarthritis—Octreotide—thymus cancer	0.00587	0.00623	CcSEcCtD
Zalcitabine—Psychotic disorder—Octreotide—thymus cancer	0.00574	0.00609	CcSEcCtD
Zalcitabine—SLC29A2—cardiac atrium—thymus cancer	0.0054	0.0939	CbGeAlD
Zalcitabine—Dry skin—Octreotide—thymus cancer	0.00538	0.00571	CcSEcCtD
Zalcitabine—Abdominal pain upper—Octreotide—thymus cancer	0.00537	0.00569	CcSEcCtD
Zalcitabine—Cramp muscle—Octreotide—thymus cancer	0.00529	0.00561	CcSEcCtD
Zalcitabine—Nasopharyngitis—Octreotide—thymus cancer	0.00525	0.00557	CcSEcCtD
Zalcitabine—Gastritis—Octreotide—thymus cancer	0.0052	0.00552	CcSEcCtD
Zalcitabine—Muscular weakness—Octreotide—thymus cancer	0.00518	0.0055	CcSEcCtD
Zalcitabine—Abdominal distension—Octreotide—thymus cancer	0.00511	0.00542	CcSEcCtD
Zalcitabine—Pancreatitis—Octreotide—thymus cancer	0.00498	0.00528	CcSEcCtD
Zalcitabine—Sweating increased—Octreotide—thymus cancer	0.00495	0.00525	CcSEcCtD
Zalcitabine—Dysuria—Octreotide—thymus cancer	0.00475	0.00504	CcSEcCtD
Zalcitabine—Pollakiuria—Octreotide—thymus cancer	0.00469	0.00498	CcSEcCtD
Zalcitabine—Weight decreased—Octreotide—thymus cancer	0.00459	0.00487	CcSEcCtD
Zalcitabine—Hyperglycaemia—Octreotide—thymus cancer	0.00458	0.00486	CcSEcCtD
Zalcitabine—SLC29A2—thyroid gland—thymus cancer	0.00455	0.0791	CbGeAlD
Zalcitabine—Depression—Octreotide—thymus cancer	0.00451	0.00479	CcSEcCtD
Zalcitabine—Neuropathy peripheral—Octreotide—thymus cancer	0.00444	0.00471	CcSEcCtD
Zalcitabine—Jaundice—Octreotide—thymus cancer	0.00441	0.00468	CcSEcCtD
Zalcitabine—Epistaxis—Octreotide—thymus cancer	0.00427	0.00453	CcSEcCtD
Zalcitabine—Sinusitis—Octreotide—thymus cancer	0.00425	0.00451	CcSEcCtD
Zalcitabine—Rhinitis—Octreotide—thymus cancer	0.00407	0.00432	CcSEcCtD
Zalcitabine—Hepatitis—Octreotide—thymus cancer	0.00406	0.00431	CcSEcCtD
Zalcitabine—Pharyngitis—Octreotide—thymus cancer	0.00403	0.00428	CcSEcCtD
Zalcitabine—Visual impairment—Octreotide—thymus cancer	0.00392	0.00416	CcSEcCtD
Zalcitabine—Tinnitus—Octreotide—thymus cancer	0.00379	0.00402	CcSEcCtD
Zalcitabine—Flushing—Octreotide—thymus cancer	0.00377	0.004	CcSEcCtD
Zalcitabine—Arrhythmia—Octreotide—thymus cancer	0.00363	0.00385	CcSEcCtD
Zalcitabine—Alopecia—Octreotide—thymus cancer	0.00359	0.00381	CcSEcCtD
Zalcitabine—SLC29A1—hematopoietic system—thymus cancer	0.00353	0.0613	CbGeAlD
Zalcitabine—Flatulence—Octreotide—thymus cancer	0.00349	0.0037	CcSEcCtD
Zalcitabine—Tension—Octreotide—thymus cancer	0.00347	0.00368	CcSEcCtD
Zalcitabine—Nervousness—Octreotide—thymus cancer	0.00344	0.00365	CcSEcCtD
Zalcitabine—Back pain—Octreotide—thymus cancer	0.00342	0.00363	CcSEcCtD
Zalcitabine—Muscle spasms—Octreotide—thymus cancer	0.0034	0.00361	CcSEcCtD
Zalcitabine—DCK—hematopoietic system—thymus cancer	0.00337	0.0586	CbGeAlD
Zalcitabine—Vision blurred—Octreotide—thymus cancer	0.00333	0.00354	CcSEcCtD
Zalcitabine—Tremor—Octreotide—thymus cancer	0.00331	0.00352	CcSEcCtD
Zalcitabine—Ill-defined disorder—Octreotide—thymus cancer	0.00328	0.00348	CcSEcCtD
Zalcitabine—Anaemia—Octreotide—thymus cancer	0.00327	0.00347	CcSEcCtD
Zalcitabine—Agitation—Octreotide—thymus cancer	0.00325	0.00345	CcSEcCtD
Zalcitabine—Malaise—Octreotide—thymus cancer	0.00319	0.00338	CcSEcCtD
Zalcitabine—Vertigo—Octreotide—thymus cancer	0.00318	0.00337	CcSEcCtD
Zalcitabine—Syncope—Octreotide—thymus cancer	0.00317	0.00337	CcSEcCtD
Zalcitabine—Palpitations—Octreotide—thymus cancer	0.00313	0.00332	CcSEcCtD
Zalcitabine—Loss of consciousness—Octreotide—thymus cancer	0.00311	0.0033	CcSEcCtD
Zalcitabine—Cough—Octreotide—thymus cancer	0.00309	0.00328	CcSEcCtD
Zalcitabine—Convulsion—Octreotide—thymus cancer	0.00307	0.00325	CcSEcCtD
Zalcitabine—Hypertension—Octreotide—thymus cancer	0.00305	0.00324	CcSEcCtD
Zalcitabine—Myalgia—Octreotide—thymus cancer	0.00301	0.0032	CcSEcCtD
Zalcitabine—Arthralgia—Octreotide—thymus cancer	0.00301	0.0032	CcSEcCtD
Zalcitabine—Anxiety—Octreotide—thymus cancer	0.003	0.00318	CcSEcCtD
Zalcitabine—Discomfort—Octreotide—thymus cancer	0.00298	0.00316	CcSEcCtD
Zalcitabine—Dry mouth—Octreotide—thymus cancer	0.00295	0.00313	CcSEcCtD
Zalcitabine—Oedema—Octreotide—thymus cancer	0.00289	0.00306	CcSEcCtD
Zalcitabine—Infection—Octreotide—thymus cancer	0.00287	0.00304	CcSEcCtD
Zalcitabine—Shock—Octreotide—thymus cancer	0.00284	0.00301	CcSEcCtD
Zalcitabine—Thrombocytopenia—Octreotide—thymus cancer	0.00283	0.003	CcSEcCtD
Zalcitabine—SLC29A2—lymph node—thymus cancer	0.00283	0.0491	CbGeAlD
Zalcitabine—Tachycardia—Octreotide—thymus cancer	0.00282	0.00299	CcSEcCtD
Zalcitabine—Skin disorder—Octreotide—thymus cancer	0.0028	0.00298	CcSEcCtD
Zalcitabine—Hyperhidrosis—Octreotide—thymus cancer	0.00279	0.00296	CcSEcCtD
Zalcitabine—Anorexia—Octreotide—thymus cancer	0.00275	0.00292	CcSEcCtD
Zalcitabine—SLC29A1—cardiac atrium—thymus cancer	0.00268	0.0466	CbGeAlD
Zalcitabine—Musculoskeletal discomfort—Octreotide—thymus cancer	0.00263	0.00279	CcSEcCtD
Zalcitabine—SLC29A1—pituitary gland—thymus cancer	0.00262	0.0455	CbGeAlD
Zalcitabine—Insomnia—Octreotide—thymus cancer	0.00261	0.00277	CcSEcCtD
Zalcitabine—Dyspnoea—Octreotide—thymus cancer	0.00257	0.00273	CcSEcCtD
Zalcitabine—Somnolence—Octreotide—thymus cancer	0.00257	0.00272	CcSEcCtD
Zalcitabine—DCK—cardiac atrium—thymus cancer	0.00256	0.0445	CbGeAlD
Zalcitabine—Dyspepsia—Octreotide—thymus cancer	0.00254	0.0027	CcSEcCtD
Zalcitabine—Decreased appetite—Octreotide—thymus cancer	0.00251	0.00266	CcSEcCtD
Zalcitabine—DCK—pituitary gland—thymus cancer	0.0025	0.0434	CbGeAlD
Zalcitabine—Fatigue—Octreotide—thymus cancer	0.00249	0.00264	CcSEcCtD
Zalcitabine—SLC29A1—lymphoid tissue—thymus cancer	0.00248	0.0432	CbGeAlD
Zalcitabine—Pain—Octreotide—thymus cancer	0.00247	0.00262	CcSEcCtD
Zalcitabine—Feeling abnormal—Octreotide—thymus cancer	0.00238	0.00252	CcSEcCtD
Zalcitabine—DCK—lymphoid tissue—thymus cancer	0.00237	0.0412	CbGeAlD
Zalcitabine—Gastrointestinal pain—Octreotide—thymus cancer	0.00236	0.0025	CcSEcCtD
Zalcitabine—Urticaria—Octreotide—thymus cancer	0.00229	0.00243	CcSEcCtD
Zalcitabine—Body temperature increased—Octreotide—thymus cancer	0.00228	0.00242	CcSEcCtD
Zalcitabine—Abdominal pain—Octreotide—thymus cancer	0.00228	0.00242	CcSEcCtD
Zalcitabine—SLC29A1—bone marrow—thymus cancer	0.00226	0.0393	CbGeAlD
Zalcitabine—SLC29A1—thyroid gland—thymus cancer	0.00226	0.0392	CbGeAlD
Zalcitabine—DCK—bone marrow—thymus cancer	0.00216	0.0375	CbGeAlD
Zalcitabine—DCK—thyroid gland—thymus cancer	0.00215	0.0375	CbGeAlD
Zalcitabine—Hypersensitivity—Octreotide—thymus cancer	0.00213	0.00226	CcSEcCtD
Zalcitabine—Asthenia—Octreotide—thymus cancer	0.00207	0.0022	CcSEcCtD
Zalcitabine—SLC29A1—lung—thymus cancer	0.00205	0.0356	CbGeAlD
Zalcitabine—Pruritus—Octreotide—thymus cancer	0.00204	0.00217	CcSEcCtD
Zalcitabine—Diarrhoea—Octreotide—thymus cancer	0.00198	0.0021	CcSEcCtD
Zalcitabine—DCK—lung—thymus cancer	0.00196	0.034	CbGeAlD
Zalcitabine—Dizziness—Octreotide—thymus cancer	0.00191	0.00203	CcSEcCtD
Zalcitabine—Vomiting—Octreotide—thymus cancer	0.00184	0.00195	CcSEcCtD
Zalcitabine—Rash—Octreotide—thymus cancer	0.00182	0.00193	CcSEcCtD
Zalcitabine—Dermatitis—Octreotide—thymus cancer	0.00182	0.00193	CcSEcCtD
Zalcitabine—Headache—Octreotide—thymus cancer	0.00181	0.00192	CcSEcCtD
Zalcitabine—CYP3A5—hematopoietic system—thymus cancer	0.00174	0.0303	CbGeAlD
Zalcitabine—CYP2C9—hematopoietic system—thymus cancer	0.00172	0.0299	CbGeAlD
Zalcitabine—SLC29A1—lymph node—thymus cancer	0.0014	0.0244	CbGeAlD
Zalcitabine—DCK—lymph node—thymus cancer	0.00134	0.0233	CbGeAlD
Zalcitabine—CYP3A4—hematopoietic system—thymus cancer	0.00131	0.0228	CbGeAlD
Zalcitabine—CYP2D6—hematopoietic system—thymus cancer	0.00129	0.0224	CbGeAlD
Zalcitabine—CYP3A5—lung—thymus cancer	0.00101	0.0176	CbGeAlD
